europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

EuropaBio response to the public consultation on the proposal for a Regulation on substances of human origin (SoHO)

07/09/2022
PRESS RELEASE
EuropaBio response to the public consultation on the proposal for a Regulation on substances of human origin (SoHO)

EuropaBio welcomes the adoption of the proposal for a Regulation on SoHO revising the EU’s Blood, Tissues, and Cells (BTC) legislation. The EU needs a predictable, future-proof, and robust SoHO framework to ensure the uptake of transformative advanced therapies which hold great potential for both the health and wellbeing of patients and the sustainability of healthcare systems. The revision of the BTC legislation is important for the ATMP sector as requirements for donation, procurement and testing apply to SoHO used in the production of ATMPs.

EuropaBio considers the proposal to be an opportunity for convergence of requirements across Member States and ensure that regulatory standards protecting patient safety and public health keep pace with technical and scientific advances. EuropaBio welcomes the proposal’s definitions and interplay with the ATMP Regulation and considers that they should be maintained in the adopted Regulation.

EuropaBio is concerned about instances where the SoHO Regulation would interfere with the EU rules on medicinal products. Classification decisions from SoHO Coordination Board could contradict the decisions of the EMA’s Committee for Advanced Therapies (CAT) which currently participates in providing scientific recommendations on the classification of ATMPs. Such situations would add unnecessary uncertainty and burden for developers of ATMPs. EuropaBio is likewise concerned as regards the reference to genetically modified organisms (GMOs) in the proposal’s recital and considers that ATMPs that consist of or contain GMOs should continue to be regulated by the ATMP Regulation.

EuropaBio believes that the governance of the new SoHO framework could be further strengthened to avoid divergence between Member States over time. The governance should also enable collaborative dialogue with industry stakeholders and the EMA’s CAT to facilitate the resolution of classification issues for borderline products. This collaborative dialogue will be particularly important for technical expert bodies like EDQM and ECDC as they develop or update technical guidelines to help adapt the legislation to scientific progress.

Additional clarifications are also necessary to avoid legal uncertainty with respect to the equivalence assessment referred to in Article 23, the recognition of the SoHO establishment authorisation in another Member State in Article 25, and the content of the EU SoHO Platform in Article 41.

The revision is also important to improve the sustainability of supply of SoHO across the EU for both direct administration and the manufacture of products derived from SoHO. However, certain provisions of the proposal, specifically Articles 42-44, could interfere with the pharmaceutical legislation as regards the distribution of SoHOs used in medicinal products manufacturing. EuropaBio believes the proposal insufficiently guarantees access to SoHO for the pharmaceutical companies and manufacturers of SoHO-derived products and encourages the co-legislators to introduce the principles of equal treatment and non-discrimination to access to SoHO to the Regulation. It is important that the legislation supports Member States in ensuring reliable supply of essential SoHO, including plasma for fractionation to manufacture plasma-derived therapies to address Europe’s reliance on the US for this essential starting material. As such, while we welcome the differentiation between plasma for fractionation and blood components for transfusion, we are concerned to see plasma donation defined as a “procedure of significant risk” without scientific justification as this may discourage plasma donations.

As the European Association of innovative biopharmaceutical and biotechnology companies representing developers of cell-based and plasma-derived medicines, EuropaBio is committed to supporting patient access to essential and innovative therapies and to becoming a global leader in ATMP innovation.

EuropaBio response to the public consultation on the proposal for a Regulation on substances of human origin (SoHO)


Download
EuropaBio response public consultation SoHODownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

31/01/2023

EuropaBio’s 2022 Patient BioForum sets out recommendations to address the challenges of patients with unmet medical needs and calls for multi-stakeholder approach


Read more
17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
17/01/2023

EuropaBio launches Industry Advisory Group for new Biomanufacturing Platform


Read more
16/01/2023

SwiftPharma joins EuropaBio: pioneering sustainable, scalable and affordable plant-made therapeutic proteins


Read more

Important links

  • Delivering Europe’s ambitions in rare disease
  • Joint Statement: The Data Act is a leap into the unknown

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies